These results are of particular importance, as they represent the first study showing the expression status of STC2 in NPC may be a potential prognostic biomarker, which may be used to identify patients with potentially unfavorable outcomes prior to the initiation of treatment; these patients may benefit from a more intensive therapeutic regimen. Here, STC2 is linked to nasopharyngeal carcinoma.